Search Results for: G1 Therapeutics Announces Clinical Trial
Articles
August 31, 2022
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 in MPS II (Hunter Syndrome) August 31, 2022
Denali Therapeutics Inc. recently announced new interim results from a Phase 1/2 trial of DNL310 (ETV:IDS) in MPS II (Hunter...
May 2, 2022
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi May 2, 2022
Denali Therapeutics Inc. recently announced its partner Sanofi has commenced dosing in a Phase 2 study, named HIMALAYA, of SAR443820...
April 11, 2022
Context Therapeutics Announces Encouraging Preclinical Data From Two Programs April 11, 2022
Context Therapeutics Inc. recently announced encouraging preclinical data from two pipeline programs, including in vivo combination and immunomodulation data evaluating onapristone...
January 25, 2022
Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma January 25, 2022
Checkpoint Therapeutics, Inc. recently announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its...
September 15, 2021
Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS September 15, 2021
Denali Therapeutics Inc. recently announced that dosing recently commenced in a Phase 1b study of DNL343, its brain-penetrant small molecule activator...
September 8, 2021
MacroGenics Announces Final Overall Survival Results From SOPHIA Study of MARGENZA in Patients with HER2-Positive Metastatic Breast Cancer September 8, 2021
MacroGenics, Inc. recently announced the final overall survival (OS) results of the SOPHIA Phase 3 study in adult patients with metastatic HER2-positive breast cancer…..
May 26, 2021
Onconova Therapeutics Announces Initial Dosing of First Patient in US Phase 1 Clinical Trial May 26, 2021
Onconova Therapeutics, Inc. recently announced the first patient has been dosed in the US Phase 1 clinical trial of ON...
May 12, 2021
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab May 12, 2021
Checkpoint Therapeutics, Inc. recently announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (cSCC) cohort in its registration-enabling clinical trial of….
March 10, 2021
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical Study March 10, 2021
AIM ImmunoTech Inc. recently announced it has dosed the first healthy subjects in its Phase 1 clinical study on the...
January 4, 2021
Inozyme Pharma Announces Authorization to Proceed in US & UK With Phase 1/2 Clinical Trial January 4, 2021
Inozyme Pharma, Inc. recently announced the US FDA has cleared the company’s Investigational New Drug (IND) application and that the...
September 15, 2020
Novus Announces Acquisition of Anelixis September 15, 2020
Novus Therapeutics, Inc. recently announced it has completed the acquisition of Anelixis Therapeutics, Inc., a privately held clinical-stage biotechnology company developing a next-generation….
September 9, 2020
Spero Therapeutics Announces Positive Topline Results From its Phase 3 ADAPT-PO Clinical Trial September 9, 2020
Spero Therapeutics, Inc. recently announced positive topline results from ADAPT-PO, the pivotal Phase 3 clinical trial evaluating Spero’s oral antibiotic...
August 19, 2020
G1 Therapeutics Announces Acceptance & Priority Review of NDA August 19, 2020
G1 Therapeutics, Inc. recently announced the US FDA has accepted the New Drug Application (NDA) for trilaciclib for small cell...
July 27, 2020
NGM Bio Announces Initiation of Phase 2 CATALINA Study July 27, 2020
NGM Biopharmaceuticals, Inc. recently announced it has initiated the Phase 2 CATALINA study, a multicenter, randomized, double-masked, sham-controlled clinical trial, to evaluate the safety and efficacy of….
May 13, 2020
Fortress Biotech Announces Exclusive Worldwide License Agreement With Columbia University May 13, 2020
Fortress Biotech, Inc. recently announced that Oncogenuity, Inc. has entered into an exclusive worldwide licensing agreement with Columbia University to develop novel….
May 5, 2020
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results May 5, 2020
TG Therapeutics, Inc. recently announced the publication of results from the multicenter Phase 2 trial evaluating ublituximab, the Company’s investigational,...
March 12, 2020
Retrophin Announces Enrollment of First 190 Patients in Pivotal Phase 3 Study March 12, 2020
Retrophin, Inc. recently announced that the first 190 patients have been enrolled in the pivotal Phase 3 DUPLEX Study evaluating...
September 24, 2019
Mustang Bio Announces Phase 1 Clinical Trial September 24, 2019
Mustang Bio, Inc. recently announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and...
August 14, 2019
Mustang Bio Announces $9.28-Million Grant to Fund Phase 1 Trial August 14, 2019
Mustang Bio, Inc. recently announced that City of Hope has received a $9.28-million grant from the California Institute for Regenerative...
August 7, 2019
Oncternal Therapeutics Announces Opening of Randomized Phase 2 Study August 7, 2019
Oncternal Therapeutics, Inc. recently announced it has opened for enrollment its randomized Phase 2 study of cirmtuzumab, a ROR1-targeted monoclonal...
